Article
Version 1
Preserved in Portico This version is not peer-reviewed
Adenylosuccinic Acid Is a Non-Toxic Small Molecule In Vitro and In Vivo
Version 1
: Received: 6 September 2023 / Approved: 6 September 2023 / Online: 7 September 2023 (05:09:43 CEST)
A peer-reviewed article of this Preprint also exists.
Timpani, C.A.; Rasmussen, L.; Rybalka, E. Adenylosuccinic Acid Is a Non-Toxic Small Molecule In Vitro and In Vivo. Pharmaceuticals 2023, 16, 1458. Timpani, C.A.; Rasmussen, L.; Rybalka, E. Adenylosuccinic Acid Is a Non-Toxic Small Molecule In Vitro and In Vivo. Pharmaceuticals 2023, 16, 1458.
Abstract
Adenylosuccinic acid (ASA) is a small molecule dicarboxylate that could be a strong clinical development candidate for inherited myopathies involving dysregulated purine nucleotide metabo-lism. Currently, there are no published pharmacokinetic/dynamic or toxicology data available, albeit 10-year clinical trial data in Duchenne muscular dystrophy patients suggests a chronically safe drug. In this study, we tested the toxicity of ASA to cultured myoblasts in vitro and acute systemic toxicity in mice. ASA is a non-toxic small molecule with an LD50> 5000mg/kg. Some background necrotic foci in the liver, kidney and gastrointestinal tract were shown that are likely incidental but warrant follow-up sub-/chronic oral exposure studies.
Keywords
adenylosuccinic acid; Duchenne muscular dystrophy; myopathy; metabolic disease; skeletal muscle; toxicology; drug development
Subject
Medicine and Pharmacology, Pharmacology and Toxicology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment